Further Study supports use of Nevisense within new Non-melanoma Skin Cancer application

These results support a new clinical application that is an important part of our growth strategy. We continue to leverage our technology platform to both add clinical value and expand the market segments we address. We believe that the Non-melanoma Skin Cancer application will help us achieve both goals, and short term be key in accelerating our growth in Germany. We look forward to releasing the application as soon as our Medical Device Regulation approval is complete, which we expect around the end of the first quarter", says Simon Grant, CEO of SciBase.

Germany, 05/02/2021 (informazione.news - comunicati stampa - scienza e tecnologia)

Simon Grant , CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com 

Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/further-study-supports-use-of-nevisense-within-new-non-melanoma-skin-cancer-application,c3280337

The following files are available for download: